Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

E2031

Sigma-Aldrich

Eliprodil

≥98% (HPLC), powder

Sinônimo(s):

α-(4-Chlorophenyl)-4-[(4-fluorophenyl)methyl]-1-piperidineethanol, SL 820715

Faça loginpara ver os preços organizacionais e de contrato

Selecione um tamanho

10 MG
R$ 1.429,00

R$ 1.429,00


Check Cart for Availability

Solicite uma grande encomenda

Selecione um tamanho

Alterar visualização
10 MG
R$ 1.429,00

About This Item

Fórmula empírica (Notação de Hill):
C20H23ClFNO
Número CAS:
Peso molecular:
347.85
Número MDL:
Código UNSPSC:
12352200
ID de substância PubChem:
NACRES:
NA.77

R$ 1.429,00


Check Cart for Availability

Solicite uma grande encomenda

Ensaio

≥98% (HPLC)

Formulário

powder

cor

white to beige

solubilidade

DMSO: 5 mg/mL, clear
H2O: insoluble

originador

Sanofi Aventis

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

OC(CN1CCC(CC1)Cc2ccc(F)cc2)c3ccc(Cl)cc3

InChI

1S/C20H23ClFNO/c21-18-5-3-17(4-6-18)20(24)14-23-11-9-16(10-12-23)13-15-1-7-19(22)8-2-15/h1-8,16,20,24H,9-14H2

chave InChI

GGUSQTSTQSHJAH-UHFFFAOYSA-N

Informações sobre genes

human ... GRIN2B(2904)
rat ... Adra1a(29412)

Ações bioquímicas/fisiológicas

NR2B selective NMDA glutamate receptor antagonist which appears to target the "polyamine site" on the NMDA receptor, setting it apart from other NR2B receptor antagonists. Possesses neuroprotective effects in models of ischemia, but prolongs the QT interval in patients; currently under investigation for acute and chronic pain.
NR2B selective NMDA glutamate receptor antagonist.

Características e benefícios

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Equipamento de proteção individual

Eyeshields, Gloves


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

P Wlaź et al.
Neuropharmacology, 38(2), 243-251 (1999-04-28)
The discovery that glutamate's activity at the N-methyl-D-aspartate (NMDA) receptor is positively modulated by glycine and polyamines has led to a new pharmacological strategy that NMDA receptor-mediated events could be antagonized indirectly at the strychnine-insensitive glycine co-agonist site (glycine(B) receptor)
O A Dravolina et al.
Pharmacology, biochemistry, and behavior, 65(4), 611-620 (2000-04-15)
Current perspectives on the clinical use of NMDA receptor antagonists infer repeated administration schedules for the management of different pathological states. The development of tolerance and cross-tolerance between different NMDA receptor antagonists may be an important factor contributing to the
P J Missel et al.
Pharmaceutical development and technology, 11(1), 87-91 (2006-03-21)
Measurement of drug release of a sparingly soluble drug by conventional methods proceeds very slowly without the aid of surfactants. Two preliminary automated methods were developed that increase sensitivity and accelerate such studies by working at very small reservoir volumes.
N A Sharif et al.
The British journal of ophthalmology, 83(2), 236-240 (1999-07-09)
This study characterised the pharmacology of [3H]-ifenprodil binding to the polyamine binding sites (PBS) on the N-methyl-D-aspartate (NMDA) receptor channel complex on human retinas. These data were correlated with the known neuroprotective effects of ifenprodil and eliprodil. Specific binding of
J E Nash et al.
Experimental neurology, 155(1), 42-48 (1999-01-27)
Current symptomatic treatment for Parkinson's disease is based largely on dopamine-replacing agents. The fact that long-term treatment with these drugs is characterized by many side effects has lead to widespread interest in nondopaminergic therapies. To date, however, it has proved

Questions

Reviews

No rating value

Active Filters

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica